Avalon GloboCare Receives Notice of Allowance for Groundbreaking CAR-T and CAR-NK Cell Technology in China
Avalon GloboCare (NASDAQ: ALBT) has received a Notice of Allowance from China's National Intellectual Property Administration for patent AVAR1901CN, co-developed with Arbele The patent covers innovative CAR-T and CAR-NK cell technology, extending Avalon's intellectual property beyond the U.S. and PCT territories.
The technology features a bispecific Anti-CD19xCD22 CAR design targeting both CD19 and CD22 antigens to minimize tumor escape risk. It also includes a localized cytokine induction system that enhances CAR cell effectiveness and activates anti-tumor immune responses specifically upon tumor engagement.
According to CEO David Jin, this platform technology aims to provide practical, cost-effective solutions for point-of-care cancer treatment, potentially improving accessibility and patient outcomes globally.
Avalon GloboCare (NASDAQ: ALBT) ha ricevuto un Avviso di Concessione dall'Amministrazione Nazionale della Proprietà Intellettuale della Cina per il brevetto AVAR1901CN, co-sviluppato con Arbele. Il brevetto copre una tecnologia innovativa di cellule CAR-T e CAR-NK, estendendo la proprietà intellettuale di Avalon oltre gli Stati Uniti e i territori PCT.
La tecnologia presenta un design bispecifico Anti-CD19xCD22 CAR che mira a colpire sia gli antigeni CD19 che CD22 per ridurre al minimo il rischio di fuga del tumore. Include anche un sistema di induzione di citochine localizzato che migliora l'efficacia delle cellule CAR e attiva risposte immunitarie anti-tumorali specificamente al contatto con il tumore.
Secondo il CEO David Jin, questa tecnologia piattaforma mira a fornire soluzioni pratiche ed economiche per il trattamento del cancro al punto di cura, potenzialmente migliorando l'accessibilità e i risultati per i pazienti a livello globale.
Avalon GloboCare (NASDAQ: ALBT) ha recibido un Aviso de Concesión de la Administración Nacional de Propiedad Intelectual de China para la patente AVAR1901CN, co-desarrollada con Arbele. La patente cubre una tecnología innovadora de células CAR-T y CAR-NK, extendiendo la propiedad intelectual de Avalon más allá de los EE. UU. y los territorios PCT.
La tecnología cuenta con un diseño bispecífico Anti-CD19xCD22 CAR que tiene como objetivo atacar tanto los antígenos CD19 como CD22 para minimizar el riesgo de escape tumoral. También incluye un sistema de inducción de citoquinas localizado que mejora la efectividad de las células CAR y activa respuestas inmunitarias anti-tumorales específicamente al interactuar con el tumor.
Según el CEO David Jin, esta tecnología de plataforma tiene como objetivo proporcionar soluciones prácticas y rentables para el tratamiento del cáncer en el punto de atención, mejorando potencialmente la accesibilidad y los resultados para los pacientes a nivel mundial.
아발론 글로보케어 (NASDAQ: ALBT)는 중국 국가 지식재산청으로부터 AVAR1901CN 특허에 대한 허가 통지를 받았습니다. 이 특허는 Arbele과 공동 개발한 혁신적인 CAR-T 및 CAR-NK 세포 기술을 포함하며, 아발론의 지식 재산권을 미국 및 PCT 지역을 넘어 확장합니다.
이 기술은 CD19와 CD22 항원을 모두 목표로 하여 종양 회피 위험을 최소화하는 이중 특이성 Anti-CD19xCD22 CAR 디자인을 특징으로 합니다. 또한, 종양과의 접촉 시에만 CAR 세포의 효과성을 높이고 항종양 면역 반응을 활성화하는 국소화된 사이토카인 유도 시스템이 포함되어 있습니다.
CEO 데이비드 진에 따르면, 이 플랫폼 기술은 치료 접근성을 개선하고 전 세계적으로 환자 결과를 향상시킬 수 있는 실용적이고 비용 효과적인 암 치료 솔루션을 제공하는 것을 목표로 하고 있습니다.
Avalon GloboCare (NASDAQ: ALBT) a reçu un Avis de Concession de l'Administration nationale de la propriété intellectuelle de Chine concernant le brevet AVAR1901CN, co-développé avec Arbele. Le brevet couvre une technologie innovante de cellules CAR-T et CAR-NK, étendant la propriété intellectuelle d'Avalon au-delà des États-Unis et des territoires PCT.
Cette technologie présente un design bispecifique Anti-CD19xCD22 CAR ciblant à la fois les antigènes CD19 et CD22 afin de minimiser le risque d'évasion tumorale. Elle comprend également un système d'induction de cytokines localisé qui améliore l'efficacité des cellules CAR et active des réponses immunitaires anti-tumorales spécifiquement lors de l'engagement tumoral.
Selon le PDG David Jin, cette technologie de plateforme vise à fournir des solutions pratiques et rentables pour le traitement du cancer sur le lieu de soins, ce qui pourrait potentiellement améliorer l'accessibilité et les résultats pour les patients à l'échelle mondiale.
Avalon GloboCare (NASDAQ: ALBT) hat eine Mitteilung über die Genehmigung vom Nationalen Amt für geistiges Eigentum Chinas für das Patent AVAR1901CN erhalten, das gemeinsam mit Arbele entwickelt wurde. Das Patent umfasst eine innovative CAR-T- und CAR-NK-Zelltechnologie, die Avalons geistiges Eigentum über die USA und PCT-Gebiete hinaus erweitert.
Die Technologie weist ein bispezifisches Anti-CD19xCD22 CAR-Design auf, das sowohl CD19- als auch CD22-Antigene angreift, um das Risiko einer Tumorf Flucht zu minimieren. Sie umfasst auch ein lokalisiertes Cytokin-Induktionssystem, das die Effektivität der CAR-Zellen verbessert und spezifisch bei Tumorkontakt antitumorale Immunantworten aktiviert.
Laut CEO David Jin zielt diese Plattformtechnologie darauf ab, praktische und kosteneffiziente Lösungen für die Krebsbehandlung am Ort der Versorgung bereitzustellen, was potenziell die Zugänglichkeit und die Patientenergebnisse weltweit verbessern könnte.
- Received patent allowance in China for CAR-T and CAR-NK cell technology
- Expanded intellectual property protection to major market beyond US
- Dual-targeting technology (CD19 and CD22) reduces risk of treatment failure
- Enhanced cytokine response system improves treatment efficacy
- None.
Insights
The Notice of Allowance from CNIPA for Avalon's AVAR1901CN patent represents a significant technological breakthrough in the CAR-T and CAR-NK cell therapy landscape. The patent's dual-targeting mechanism for CD19 and CD22 antigens addresses a critical challenge in current CAR-T therapies - antigen escape, which occurs in approximately
The technology's innovative localized cytokine induction system is particularly noteworthy, as it potentially solves two major hurdles in current CAR-T therapy: cytokine release syndrome (CRS) and cell persistence. By activating cytokines only upon tumor engagement, this approach could significantly reduce systemic toxicity while enhancing treatment efficacy.
From a market perspective, this patent strengthens Avalon's position in China's rapidly growing cell therapy market, projected to reach
The dual-antigen targeting approach could potentially reduce manufacturing costs and improve treatment outcomes by decreasing the likelihood of relapse, addressing key commercial challenges in the CAR-T market. However, the path to commercialization will require extensive clinical validation and regulatory approvals, suggesting a medium to long-term timeline for revenue generation.
FREEHOLD, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced today that it has received a Notice of Allowance from the China National Intellectual Property Administration (CNIPA) for its patent application AVAR1901CN.
This patent, co-developed with Hong Kong-based Arbele Limited, marks a milestone in the advancement of chimeric antigen receptor (CAR)-based therapies. It extends Avalon’s global intellectual property footprint to China, beyond the U.S., and additional territories under the Patent Cooperation Treaty (PCT), strengthening the Company’s position in the global market.
The AVAR1901CN patent focuses on innovative technology designed to enhance the expansion, manufacturing, survival, and efficacy of CAR-T and CAR-Natural Killer (NK) cells. Its key features include:
- Bispecific Anti-CD19xCD22 CAR: This design targets both CD19 and CD22 antigens, minimizing the risk of tumor escape via antigen loss.
- Localized Cytokine Induction: The technology facilitates cytokine responses localized to tumor engagement, improving CAR cell cytotoxicity, survival, and proliferation while simultaneously activating a host anti-tumor immune response.
“The bispecific anti-CD19xCD22 CAR in this application is designed to target both CD19 and CD22 antigens, effectively reducing the risk of tumor escape due to antigen loss,” said David Jin, M.D., Ph.D., Avalon’s CEO. “This innovative approach also induces a localized cytokine response, ensuring cytokines are activated only upon tumor cell engagement. This not only enhances CAR cell cytotoxicity, survival, and proliferation but also stimulates a host anti-tumor immune response. By advancing this groundbreaking platform technology, we aim to provide practical, cost-effective, and efficient solutions for point-of-care cancer treatment. Expanding our intellectual property into China further solidifies our leadership in cell-based immunotherapy. We believe that our cutting-edge innovations will improve accessibility and lead to better outcomes for patients worldwide.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. Avalon is working to establish a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results. The Company also provides laboratory services, offering a broad portfolio of diagnostic tests, including drug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. For more information about Avalon, please visit www.avalon-globocare.com.
For the latest updates on Avalon’s developments, please follow us on X (formerly known as Twitter) at @avalongc_avco.
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates; however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of KetoAir and the product’s ability to compete with other testing methods for determining ketosis. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission (the “SEC”), accessible through the SEC’s website (http://www.sec.gov), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. The Company disclaims any obligation to update forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
FAQ
What is the significance of Avalon GloboCare's (ALBT) new patent allowance in China?
How does ALBT's bispecific CAR technology work?
What are the key features of Avalon's AVAR1901CN patent?
How might this patent impact ALBT's market position in cancer treatment?
